Circulating Tumor DNA in Patients at High Risk for Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02715102|
Recruitment Status : Terminated (Patient accrual was slow due to exclusion of patients with prior cancers)
First Posted : March 22, 2016
Last Update Posted : August 21, 2017
|Condition or disease|
|Cancer of the Lung Lung Cancer Lung Neoplasms Adenocarcinoma of the Lung Non Small Cell Carcinoma of the Lung Small Cell Carcinoma of the Lung|
Specific somatic (i.e. acquired and not inherited) mutations have been found in many cancers. Some of these cancers shed this DNA into the patient's blood stream and is called circulating tumor DNA (ctDNA). Pathway Genomics has developed a new molecular assay that uses blood plasma as the source of DNA fragments. The ctDNA is isolated, amplified and analyzed for the presence of one or more of 96 known mutations that are found in 9 cancer driver genes. This technique of using a "liquid biopsy" to screen for and monitor cancer has been documented in a number of recent medical publications. However, the majority of published studies are on subjects who have already been diagnosed with cancer. Therefore, the investigators wish to look at a population of patients who are scheduled to undergo a diagnostic or therapeutic bronchoscopy or thoracotomy without a know history of cancer (other than basal cell carcinomas of the skin). The blood will be drawn at the time of or a few weeks before the procedure. The analysis of the blood sample will take placed in the Pathway Genomics clinical laboratory which is Clinical Laboratory Improvement Amendments of 1988 (CLIA) certified.
Following an informed consent process, the patients will fill out a health questionnaire and will have the blood drawn prior to the surgical procedure. Up to 30 ml of blood (approximately 2 tablespoons) will be drawn at any one time. The patient will be asked to agree to being contacted by the investigators yearly for up to 5 years to provide follow-up medical information. No patient will be identified in presentations or publications resulting from this work and all data will be reported from analysis of combined information from participants in this study.
Individuals may participate in this study if they are 18 years of age or older, have not had a prior diagnosis of cancer (other than a skin cancer or if they are undergoing the thoracic surgical procedure for a cancer that was diagnosed within the prior month), and are undergoing a diagnostic or therapeutic bronchoscopy or thoracotomy.
|Study Type :||Observational|
|Actual Enrollment :||39 participants|
|Official Title:||Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Lung Cancer in Patients Undergoing Diagnostic or Therapeutic Bronchoscopy or Thoracotomy|
|Study Start Date :||June 2016|
|Actual Primary Completion Date :||August 2017|
|Actual Study Completion Date :||August 2017|
- Percentage of patients with lung cancer who had a positive ctDNA result (true positive) [ Time Frame: 5 years ]ctDNA results will be correlated with pathology and subsequent clinical findings.
- Percentage of patients who develop any cancer during the 5 years of follow-up [ Time Frame: 5 years ]ctDNA results will be correlated with pathology and subsequent clinical findings.
- Percentage of patients without lung cancer who had a positive ctDNA result (false positive) [ Time Frame: 5 years ]ctDNA results will be correlated with pathology and subsequent clinical findings.
- Percentage of patients with lung cancer who had a negative ctDNA result (false negative) [ Time Frame: 5 years ]ctDNA results will be correlated with pathology and subsequent clinical findings.
- Percentage of patients without lung cancer who had a negative ctDNA result (true negative) [ Time Frame: 5 years ]ctDNA results will be correlated with pathology and subsequent clinical findings.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02715102
|United States, California|
|Cardiothoracic Outpatient Clinic, Providence Saint John's Health Center, 2121 Santa Monica Blvd.|
|Santa Monica, California, United States, 90404|
|Principal Investigator:||Robert J. McKenna, M.D.||Providence Saint John's Health Center|